Nader N. Hanna, MD
Dr. Nader N. Hanna is a surgical oncologist who specializes in colorectal surgery and other abdominal surgeries at Jefferson Health in Pennsylvania. He specializes in the treatment of abdominal and GI cancers, including peritoneal mesothelioma. Dr. Hanna is skilled in the complex procedure known as cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, in which a heated chemotherapy solution is administered to a surgical site after all visible cancerous material has been removed.[1]
Education and Career
Board-certified in General Surgery with a specialty certification in Surgical Oncology, Dr. Hanna began his medical education at the Ain Shams University Faculty of Medicine in Egypt. He completed a rotating internship there and an internship in Medicine and Surgery at Deaconess Waltham Hospital in Massachusetts.
Following his internship, he was a resident in Surgery and Chief Surgical Resident at St. Elizabeth Medical Center, Tufts University School of Medicine in Boston, then completed a fellowship in Surgical Oncology and was a Postdoctoral Research Fellow in the Division of the Biological Sciences, Department of Radiation & Cellular Oncology, at the University of Chicago Pritzker School of Medicine.[1]
Following the completion of his fellowships, Dr. Hanna spent several years as a faculty member and member of the Department of Surgery at the University of Kentucky School of Medicine in Lexington and the UK Markey Cancer Center.
He then joined the faculty of the University of Maryland School of Medicine. There, he was Professor of Surgery and Director of Clinical Operations of the Division of General and Oncologic Surgery.
Today, Dr. Hanna is a surgical oncologist and faculty member at Jefferson Health and Thomas Jefferson University in Philadelphia, Pennsylvania. He specializes in colorectal surgery and hepatobiliary and pancreatic surgery.
He is one of the few surgeons able to offer peritoneal mesothelioma patients cytoreductive surgery with HIPEC. The procedure is among the most effective for patients with this rare cancer.
Dr. Hanna has several leadership and academic roles at Thomas Jefferson University and Jefferson Health:[2]
- Professor of Surgery
- Enterprise Surgeon Leader for Surgical Oncology
- Vice Chair for Cancer Services
- Director, Division of Surgical Oncology
In addition to caring for patients with malignant mesothelioma, Dr. Hanna is an expert in advanced and complex surgical oncology procedures, including esophagectomy, gastrectomy, major liver resection, Whipple procedure, and pelvic exenteration for the treatment of advanced/recurrent and metastatic gastrointestinal cancers.
Professional Memberships
- Society of Surgical Oncology
- American College of Surgeons
- American Society of Clinical Oncology
- Association for Academic Surgery
- Leadership Society of the American College of Surgeons
- International College of Surgeons
- Society of University Surgeons
- American Academy on Communications in Healthcare
Research
Dr. Hanna’s research interests include outcomes research and clinical trials as well as gene therapy for pancreatic cancer and radio-sensitization for GI malignancies.
His work has been published in highly respected journals, including Nature, Nature Medicine, Cancer Research, Human Gene Therapy, Journal of Clinical Oncology, Oncologist, Colorectal Disease, Annals of Surgical Oncology, Annals of Surgery, and Journal of the American College of Surgeons.[1]
Among his published works is a study titled “Treatment Factors Associated With Long-Term Survival Following Cytoreductive Surgery and Regional Chemotherapy for Patients with Malignant Peritoneal Mesothelioma,” published in the journal Surgery.
